MET and liver cancer: In 2009, Garofalo et al., showed that c-Met upregulates miR-221 and 222 expression through Jun transcriptional activation, which, in turn, confers resistance to TRAIL-induced cell death and increases tumorigenicity of lung and liver cancer cells by targeting PTEN and TIMP3 [59].